This is consistent with the observations that EP4 antagonist E7046 significantly inhibited M2 macrophage‐mediated hepatic stellate cells autophagy and improved liver fibrosis in NAFLD mice via suppressing ERK1/2 pathway.[40]. Here, MAPK3 is linked to metabolic dysfunction-associated steatotic liver disease.